Following its surprise swerve into the radiopharmaceutical space last month, Sanofi has doubled down by forming a joint venture with alpha therapy specialist Orano Med. The big pharma is to invest €300m ($326m) in the new entity, which will set about developing next-generation radioligand medicines for rare cancers.
Key Takeaways
- Sanofi is to form a joint venture with Orano Med to develop radiopharmaceuticals, investing €300m.
- The new group will have a valuation of $1.9bn, making it one of the larger pure-play therapeutic radioligand developers
The new company will operate under the Orano Med brand, the partners said, and will work on new molecules conjugated to lead-212
